CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← DBV Technologies S.A. (DBVT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

DBV Technologies S.A. (DBVT)

Biological Products, (No Diagnostic Substances) · market cap $783M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
DBV Technologies S.A. (DBVT) is a French biopharmaceutical company developing its proprietary Viaskin epicutaneous immunotherapy (EPIT) platform, with the lead asset Viaskin Peanut 250 mcg in Phase 3 clinical development for peanut allergy. The company carries a ~$4.9B market cap, $229M in cash representing approximately 14 months of runway, and has been burning roughly $100–120M annually on R&D with minimal revenue. The nearest listed catalyst is an August 4, 2026 earnings report.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
DBV712Phase 3Peanut Allergy
Viaskin MilkPhase 2Food Allergy
Part A Viaskin PeanutPhase 3Peanut Allergy
Viaskin PeanutPhase 3Peanut Allergy
Price & technical context
3-month
-26.8%
6-month
-47.0%
12-month
-25.9%
52-wk range
$8.87–$24.54
vs 50-day MA
-5.5%
vs 200-day MA
-37.3%
Realized vol
69.6%
Max drawdown
-63.9%

Daily closes through 2026-11-06. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for DBVT (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.